De Chao Yu
Chief Executive Officer at INNOVENT BIOLOGICS, INC.
Net worth: 526 M $ as of 30/03/2024
Profile
Founder of Innovent Biologics, Inc. and Chengdu Kanghong Pharmaceutical Group Co., Ltd., De Chao Yu occupies the position of Chairman & Chief Executive Officer at Innovent Biologics, Inc. and Chairman for Chinese Antibody Society. He is also on the board of Babytree Group and Cheerwin Group Ltd. and Professor at Sichuan University. De Chao Yu previously was President & Chief Executive Officer at Chengdu Kanghong Pharmaceutical Group Co., Ltd., Vice President-Research & Development of Applied Genetic Technologies Corp., Vice President-Research & Development at Applied Genetics, Inc., President & Chief Executive Officer for Kanghong Sagent Chengdu Pharmaceutical Corp. Ltd., Vice President-Research & Development for Calyon North America, Inc., Vice President at Calydon, Inc. and Managing Director at China Medicinal Biotech Association. He received a doctorate from Chinese Academy of Sciences.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
INNOVENT BIOLOGICS, INC.
6.73% | 21/03/2024 | 109,245,165 ( 6.73% ) | 526 M $ | 30/03/2024 |
De Chao Yu active positions
| Companies | Position | Start |
|---|---|---|
| INNOVENT BIOLOGICS, INC. | Chief Executive Officer | 27/04/2011 |
| Sichuan University | Corporate Officer/Principal | 31/12/2007 |
| Chinese Antibody Society | Chairman | 31/12/2016 |
Former positions of De Chao Yu
| Companies | Position | End |
|---|---|---|
| BABYTREE GROUP | Director/Board Member | 09/05/2023 |
| CHEERWIN GROUP LIMITED | Director/Board Member | 13/10/2022 |
| China Medicinal Biotech Association | Corporate Officer/Principal | 31/12/2018 |
| PHARMABLOCK SCIENCES (NANJING), INC. | Director/Board Member | 31/12/2017 |
| CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD | Chief Executive Officer | 31/12/2010 |
Training of De Chao Yu
| Chinese Academy of Sciences | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 5 |
|---|---|
| CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD | Health Technology |
| INNOVENT BIOLOGICS, INC. | Health Technology |
| PHARMABLOCK SCIENCES (NANJING), INC. | Commercial Services |
| BABYTREE GROUP | Commercial Services |
| CHEERWIN GROUP LIMITED | Process Industries |
| Private companies | 7 |
|---|---|
Calydon, Inc.
 Calydon, Inc. Medical SpecialtiesHealth Technology Part of ANI Pharmaceuticals, Inc., Calydon, Inc. develops therapeutic products for cancer. The private company is based in Sunnyvale, CA. Calydon was acquired by Cell Genesys, Inc. on September 05, 2001 for $17.68 million. | Health Technology |
Beacon Therapeutics (USA), Inc.
 Beacon Therapeutics (USA), Inc. Pharmaceuticals: GenericHealth Technology Applied Genetic Technologies Corp. is a clinical stage biotechnology company, which engages in the usage of a gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. The firm also focuses on conducting clinical trials in the field of ophthalmology, optogenetics, adrenoleukodystrophy, and otology. The company was founded by Richard Jude Samulski, Nicholas Muzyczka, William W. Hauswirth, Terence R. Flotte, and Barry J. Byrne on January 19, 1999 and is headquartered in Alachua, FL. | Health Technology |
Calyon North America, Inc.
 Calyon North America, Inc. Regional BanksFinance Part of SAS Rue la Boétie, Calyon North America, Inc. is a private company based in New York, NY. | Finance |
| China Medicinal Biotech Association | |
| Applied Genetics, Inc. | |
Kanghong Sagent Chengdu Pharmaceutical Corp. Ltd.
 Kanghong Sagent Chengdu Pharmaceutical Corp. Ltd. Pharmaceuticals: MajorHealth Technology Part of Ellimist Singapore Pte Ltd., Kanghong Sagent Chengdu Pharmaceutical Corp. Ltd. is a pharmaceutical company that manufactures and supplies pharmaceutical products. The private company is based in Chengdu, China. Kanghong Sagent Chengdu Pharmaceutical Corp. was acquired by Sagent Pharmaceuticals, Inc., part of Ellimist Singapore Pte Ltd. from February 28, 2023 on June 04, 2013 for $4.06 million. The Chinese company was founded in 2006. | Health Technology |
| Chinese Antibody Society |
- Stock Market
- Insiders
- De Chao Yu
